Industry Veterans from BioPharma Consultants Ltd. Boost Launch of BioSignia Inc. Pharmaceutical Technology Group; Synthesis Analysis Positioned as Critical Competitive Tool
RESEARCH TRIANGLE PARK, N.C., (Jan. 14, 2002) BioSignia Inc. has tapped two key industry insiders to help launch its newly formed Pharmaceutical Technology Group, a business unit BioSignia created earlier this year to develop pharmaceutical and biotech industry applications of its patented Synthesis Analysis technology.
Bob Keefer and Leisa Dennehy, both managing directors of BioPharma Consultants, bring a long track record of scientific, technology, business, financial, and marketing experience from throughout the industry. They are providing strategic council and business development services for BioSignias Pharmaceutical Technology Group (www.pharma.biosignia.com), whose patented predictive modeling technology can benefit drug companies in virtually all stages of product development, from discovery to clinical development to marketing. BioPharma Consultants is based in Research Triangle Park, NC a well-known technology and biotech hotbed.
Leisa Denney and Bob Keefer, through their extraordinary industry insight and experience, are able to help us articulate our technology in language thats meaningful to the right people in pharma, said Joe Chimera, Ph.D., vice president for corporate development and head of the Pharmaceutical Technology Group of BioSignia Inc. They represent a powerful strategic, scientific, and marketing force, and were very excited to be working with them.
BioSignias Pharmaceutical Technology Group currently is developing products that allow drug development scientists to build robust and discriminatory multivariate equations for predicting specific disease endpoints from all of the available longitudinal research and clinical trial studies. In addition to this, the Pharmaceutical Technology Group can help pharmaceutical companies efficiently recruit and enroll patients for clinical trials, provide earlier insight into drug efficacy safety, and cost effectiveness, and enhance the support of physicians by helping them fully consider all available evidence regarding the diagnosing of chronic disease.
We see enormous possibilities in the technology BioSignia has developed, said Keefer, who holds a Ph.D. in medical biochemistry and has held a number of executive positions with major pharmaceutical companies and start-up companies. This could be a game-changer for many companies.
Once the right people begin to understand the applications of Synthesis Analysis technology, then well see real changes in how pharma and biotech approach drug development, said Dennehy, who has more than 14 years of domestic and international marketing experience with the industrys largest multinational companies.
BioSignia, Inc. is a life sciences research organization that specializes in understanding the epidemiology of slowly developing multifactor diseases. The company develops cutting-edge predictive technologies for determining risk for morbidity and/or mortality and embeds these technologies in comprehensive systems that augment decisions related to patient care, drug development and marketing, and actuarial sciences. More information on these technologies can be found at http://www.biosignia.com. Through its business groups, BioSignia focuses on the unique needs of each sector.
Contacts: Joe Chimera BioSignia, Inc 919-933-2021